CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Anti-SARS-CoV-2 IgT seropositivityWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug2900 mortality Wiki 1.00

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Epidemiological Study of Seroprevalence Against the SARS-CoV-2 Virus (COVID-19) in the Population of the Grand Nancy Metropolitan Area

In order to inform the public decision on the containment strategy and knowledge of the intensity of the epidemic during post-containment, estimates of the share of the population infected with the SARS-CoV-2 virus responsible for COVID-19 disease at the territorial level are needed as soon as possible. The aim of the study is to estimate the prevalence of positive anti-SARS-CoV-2 serologies by detection of IgT-total antibodies (IgM/IgA/IgG) in the general population of the Grand Nancy Metropolitan area. A study of seroprevalence and symptom collection, or absence of symptoms, on a cluster (household) sample of the Grand Nancy Metropolitan population randomly selected will be conducted. The target population consists of all the inhabitants of the Grand Nancy Metropolitan area, from which a sample is drawn from the electoral lists (households) in a random manner to ensure representativeness. In order to ultimately include 2000 people in the study

NCT04448769 Coronavirus Infection Prevalence Biological: Anti-SARS-CoV-2 IgT seropositivity
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: Anti-SARS-CoV-2 IgT seropositivity of the individuals tested in the population of the Grand Nancy Metropolitan area

Measure: Anti-SARS-CoV-2 IgT (IgM/IgA/IgG) seropositivity

Time: through study completion, an average of 4 hours

Secondary Outcomes

Description: To estimate the proportion of occurrence of an episode of clinical symptoms since the beginning of the epidemic among seropositive people using self report questionnaires.

Measure: Proportion of asymptomatic, symptomatic cases among seropositive people

Time: through study completion, an average of 4 hours

Description: To estimate the proportion of asymptomatic cases (asymptomatic fraction) by the proportion of seropositive individuals who did not show any sign or symptom of COVID-19 since the beginning of the epidemic in France (mid-February).

Measure: Proportion of asymptomatic cases among seropositive people

Time: through study completion, an average of 4 hours

Description: To understand susceptibility factors to infection by comparing infected and uninfected persons on the basis of age, sex, weight status, smoking status, occupation and education.

Measure: Identification of risk groups - Anti-SARS-CoV-2 IgT seropositivity by age, sex and as a function of weight status, smoking status, work activity and social status.

Time: through study completion, an average of 4 hours

Description: Determining the prevalence of seropositive people according to the level of social disadvantage

Measure: Proportion of seropositive subjects according to the level of social disadvantage measured by the EPICES score

Time: through study completion, an average of 4 hours

Description: To estimate the prevalence of infected households

Measure: Proportion of infected households

Time: through study completion, an average of 4 hours

Description: To provide knowledge on intra-household dissemination

Measure: Anti-SARS-CoV-2 IgT seropositivity in the household

Time: through study completion, an average of 4 hours

Description: To develop symptom association profiles in seropositive subjects

Measure: Clinical expression patterns of infection by symptom/antibody association

Time: through study completion, an average of 4 hours

Description: To study the serum distribution of seropositive people, particularly in each symptom typology group.

Measure: Serological Response to Infection

Time: through study completion, an average of 4 hours

Description: To use the results of the SARS-CoV-2 seroprevalence testing campaign and questionnaires to refine our knowledge of the current and future situation and make better projections with better calibrated mathematical models of SIR infectious diseases.

Measure: Anti-SARS-CoV-2 IgT seropositivity

Time: through study completion, an average of 4 hours

Description: 10. To evaluate the in vitro neutralisation capacity of the viral infectivity of the antibodies detected.

Measure: • Evaluation of serum neutralisation of persons positive for anti-SARS-CoV-2 antibodies, of the infectivity of viral strains in cell culture: percentage neutralisation compared to a viral strain not exposed to seropositive serum.

Time: through study completion, an average of 4 hours

No related HPO nodes (Using clinical trials)